#USA #San Diego #Neurelis #VALTOCO #Craig Chambliss

Neurelis CEO Craig Chambliss to Speak at Outsourcing in Clinical Trials Conference

In a significant announcement for the clinical research community, Neurelis, Inc. has revealed that its founder and CEO, Craig Chambliss, will serve as the keynote speaker at the upcoming 14th Annual Outsourcing Clinical Trials (OCT) Southern California conference. This prestigious event is scheduled to occur on September 15-16, 2026, at the Hyatt Regency La Jolla in San Diego, California.

As the innovator behind the breakthrough VALTOCO® (diazepam nasal spray), Neurelis is at the forefront of developing therapeutics aimed at treating epilepsy and neurological disorders. Chambliss expressed his gratitude for the opportunity, stating, "I am honored to have been invited to join in the dialogue on advances in clinical research and development with other biotech and pharma leaders." His keynote presentation is titled "Unlocking the Power of Clinical Data: Turning Study Results into Long-Term Strategic Insights."

Focus on Clinical Data Strategy

During his address, Chambliss plans to delve into a vital aspect of clinical research: the strategic use of clinical data. He will discuss how Neurelis has successfully leveraged clinical data to create impactful publications, which significantly contribute to the understanding of epilepsy among healthcare professionals, researchers, and patients alike. This focus on data not only enhances educational efforts but also sets the stage for ongoing dialogue and advancement in treatment approaches.

The keynote will explore strategies for analyzing clinical data to yield insights beyond initial study objectives and to highlight the significance of various population subsets affected by epilepsy. The narrative Chambliss intends to weave underscores how the VALTOCO clinical study data has played a crucial role in fostering education and awareness within the epilepsy community.

Conference Overview

The OCT Southern California conference is a key gathering for leaders in the biopharmaceutical industry, including sponsors, biotech companies, and Contract Research Organizations (CROs). It serves as an excellent platform for exchanging insights, forging strategic partnerships, and discussing the latest innovations in clinical development. The event is organized by GlobalData Healthcare and Arena International, further emphasizing its credibility and relevance in the industry.

Attendees can expect a series of discussions, panels, and networking sessions aimed at addressing current challenges and opportunities in clinical trials. From regulatory hurdles to the integration of new technologies, this event promises to cover a wide range of topics pertinent to clinical research professionals.

About Neurelis

Neurelis, Inc. is committed to addressing critical needs within the epilepsy therapeutic landscape. With the FDA's approval of VALTOCO for treating acute seizure clusters in patients aged two years and older, the company is pioneering advancements in the care of individuals experiencing seizure disorders.

In addition to VALTOCO, Neurelis is actively developing other investigational drugs, including NRL-1004, aimed at treating acute agitation episodes associated with schizophrenia and bipolar disorder, and NRL-1049, a potential treatment for cerebral cavernous malformations. For detailed insights into VALTOCO and the ongoing research by Neurelis, interested individuals are encouraged to visit www.neurelis.com and www.valtoco.com.

Conclusion

As the clinical trials landscape continues to evolve, the contributions of leaders like Craig Chambliss and organizations like Neurelis are critical. Their commitment to leveraging clinical data for enhanced treatment outcomes exemplifies the ongoing progress in medical research and patient care. The upcoming conference promises to be a cornerstone event for professionals looking to stay at the forefront of clinical development.